Article Text

Download PDFPDF
Role of biological therapy for inflammatory bowel disease in developing countries
  1. Naila Arebi
  1. Correspondence to Dr Naila Arebi, Imperial College, St Mark's Hospital, Watford Road, London HA1 3UJ, UK; naila.arebi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

I would like to comment on the interesting manuscript by Rogler et al.1 The authors highlight the rising incidence of Inflammatory Bowel Disease (IBD) in the developing world and express concern how such countries might finance the escalation of Biological therapy. They describe the barriers to access of these drugs, namely lack of infrastructure for financing and monitoring drug treatment. In their discussion, they explore how best to treat severe IBD in this context and argue that transfer of experience of anti-tumour necrosis factor agents from experts in the West to developing countries offers a means of increasing access to …

View Full Text


  • Competing interest None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles